U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07494435) titled 'Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC' on March 16.
Brief Summary: This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.
Study Start Date: June 01, 2026
Study Type: INTERVENTIONAL
Condition:
Hepato Cellular Carcinoma (HCC)
Renal Cell Cancer
Intervention:
DRUG: WGI-0301
WGI-0301 at Maximum Tolerated Dose ...